drugset / Trial / NCT03830463

Study to Assess the Safety and Pharmacokinetic (PK) of CTP-692 in Healthy Volunteers

NCT03830463

Phase 1 Completed 42 enrolled Concert Pharmaceuticals
RandomizedSequentialQuadruple-blindTreatment

Summary

This study will assess the safety and pharmacokinetic (PK) profile of single ascending doses of CTP-692 in healthy volunteers.

Timeline

Start
2019-01-24
Primary completion
2019-03-28
Completion
2019-03-28

Drugs

EvaluationDrugModalityDoseRoute
Subject CTP-692 Unknown Oral

Indications

No indication recorded.